22 May 2013
Keywords: CEl-SCI Corp, Multikine, Advertising, USA, FDA, Head and neck cancer
Article | 22 August 2011
US drug developer CEL-SCI Corp (NYSE AMEX: CVM) says it received a warning letter received from the Division of Drug ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
22 August 2011
23 August 2011
21 May 2013
© 2013 thepharmaletter.com